General
Preferred name
PANOBINOSTAT
Synonyms
LBH-589 ()
NVP-LBH589 ()
LBH589 ()
LBH589 (Panobinostat) ()
LBH 589 ()
Panobinostat (lactate) ()
PanobinostatNVP-LBH-589FarydakLBH-589P-3703A-1025LBH589 ()
LBH589 (lactate) ()
NVP-LBH589 (lactate) ()
Panobinostat (LBH589) ()
Farydak ()
Panobinostat hydrate ()
Panobinostat lactate anhydrous ()
PANOBINOSTAT LACTATE ()
Panobinostat-d4 ()
P&D ID
PD003575
CAS
404950-80-7
960055-56-5
Tags
available
obsolete probe
drug
Approved by
EMA
FDA
First approval
2015
Drug indication
Primary myelofibrosis
Neoplasm
Type-2 diabetes
Multiple myeloma
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Panobinostat is a non-selective histone deacetylase (HDAC) inhibitor . The compound also has antimalarial activity.
The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY. (GtoPdb)
The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY. (GtoPdb)
DESCRIPTION
Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].
PRICE
39
DESCRIPTION
Panobinostat lactate is a potent and orally active non-selective HDAC inhibitor. Panobinostat lactate has antineoplastic activities. Panobinostat lactate effectively disrupts HIV latency. Panobinostat lactate induces cell apoptosis and autophagy. Panobinostat lactate can be used for the study of refractory or relapsed multiple myeloma[1][2][3][4][5].
DESCRIPTION
inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8
(Informer Set)
DESCRIPTION
Panobinostat is a non-selective histone deacetylase inhibitor used to treat multiple myeloma in combination with other antineoplastic agents.
(Enamine Bioactive Compounds)
DESCRIPTION
Panobinostat (NVP-LBH589) is a broad-spectrum HDAC inhibitor (IC50=5 nM) with oral activity and non-selectivity. Panobinostat has antitumor activity and induces apoptosis and autophagy.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
24
Organisms
2
Compound Sets
29
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Guide to Pharmacology
Informer Set
LSP-MoA library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
Nuisance compounds in cellular assays
NURSA ligand set
Obsolete Compounds
Pandemic Response Box
Reference compounds for characterizing cellular injury in high-content cellular morphology assays
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
416
Molecular Weight
349.18
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
4
Rotatable Bonds
7
Ring Count
3
Aromatic Ring Count
3
cLogP
3.33
TPSA
77.15
Fraction CSP3
0.19
Chiral centers
0.0
Largest ring
6.0
QED
0.23
Structural alerts
2
historic compounds (Chemical Probes.org)
Obsolete
Nonspecific HDAC inhibition
Nuisance compounds
Custom attributes
(extracted from source data)
Target
HDAC1
HDAC2
HDAC3
HDAC6
HDAC8
HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9
Apoptosis related,Autophagy,HDAC,HIV Protease
HIV
Compound status
clinical
MOA
HDAC
HDACs
Apoptosis Inducers
Histone Deacetylase (HDAC) Inhibitors
HDAC inhibitor
Member status
virtual
Indication
multiple myeloma
Pathway
Apoptosis
Autophagy
Chromatin/Epigenetic
DNA Damage/DNA Repair
Microbiology/virology
Proteases/Proteasome
Anti-infection
Cell Cycle/DNA Damage
Epigenetics
Source data

